Clinical review: Status epilepticus by Bassin, Sarice et al.
ASE = acute status epilepticus; EEG = electroencephalograph; GCSE = generalized convulsive status epilepticus; NCSE = nonconvulsive status
epilepticus; SE = status epilepticus.
Available online http://ccforum.com/content/6/2/137
Status epilepticus (SE) is a medical and neurologic emer-
gency. Given the significant risk of mortality, and the possibil-
ity of successful therapeutic intervention, it is essential for all
physicians to be able to efficiently identify and treat patients
in SE.
Definition
The definition of SE is based on the clinical manifestation, a
prolonged seizure or a series of seizures during which the
patient has incomplete recovery of consciousness, and dura-
tion. The duration parameter is controversial and has created
a flux in our definition of SE. In their 1981 definition of SE, the
International League Against Epilepsy describes the time ele-
ments as “sufficient length” and “frequently enough” [1]. For
definition and management purposes, both of these quanti-
fiers are ambiguous.
Elegant animal studies in the 1970s and 1980s revealed sig-
nificant damage to the brain after 30 minutes of seizure activ-
ity, even with control of blood pressure, respiration, and body
temperature [2–4]. These studies lent credence to the choice
of 30 minutes as a specific time point to define SE. Although
seizures can spontaneously remit after 10 to 29 minutes [5],
in studies of the natural course of generalized tonic-clonic
seizures, it has been well documented that, in humans, most
seizures will terminate spontaneously within a few minutes
[6]. For this reason, it has been proposed that an operational
definition of SE should involve timing much shorter than
30 minutes [7].
The operational definition of SE proposed by Lowenstein,
Bleck, and Macdonald is a continuous, generalized, convul-
sive seizure lasting greater than five minutes (in an adult or
child older than five years), or two or more seizures during
which the patient does not return to baseline consciousness
[7]. Recent treatment studies including the Veterans Adminis-
tration Cooperative Trial on Treatment of SE and the Pre-
Hospital Treatment of SE study have used times of ten and
five minutes respectively [8,9]. For treatment purposes, it is
more practical to conceptualize SE using these narrower time
windows. Shinnar et al. analyzed the duration of new-onset
seizure activity in 407 children, and concluded that seizures
lasting longer than five to ten minutes were unlikely to stop
spontaneously, and should be treated [10].
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Abstract
Status epilepticus (SE) has an annual incidence exceeding 100,000 cases in the United States alone,
of which more than 20% result in death. Thus, increased awareness of presentation, etiologies, and
treatment of SE is essential in the practice of critical care medicine. This review discusses current
definitions of SE, as well as its clinical presentation and classification. The recent literature on
epidemiology is reviewed, including morbidity and mortality data. An overview of the systemic
pathophysiologic effects of SE is presented. Finally, significant studies on the treatment of acute SE
and refractory SE are reviewed, including the use of anticonvulsants, such as benzodiazepines, and
other drugs.
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Clinical manifestations and classification
The classification systems used for SE are discrepant
throughout the literature. Many schemes have been gener-
ated that rely on both clinical and electrographic findings. It is
important to note that virtually all seizure types may become
prolonged, thereby fulfilling the definition of SE [11]. In an
effort to provide a simple overview, a clinical approach will be
favored here.
Prolonged convulsions with impaired consciousness consti-
tutes generalized convulsive SE (GCSE). Although a patient
with convulsions is easily recognized, some patients who
have been in GCSE may progress to have minimal or no
apparent motor activity but still show seizures on an electro-
encephalograph (EEG) [12]. The clinician must be aware of
this situation, because aggressive treatment for this group
is just as important as it is for the obviously convulsing
patient [13].
The patient with nonconvulsive SE (NCSE) can exhibit a wide
variety of clinical manifestation including coma, confusion,
somnolence, altered affect, fugue states, aphasia, abnormal
autonomic/vegetative symptoms, delusions, hallucinations,
and paranoia [14]. The NCSE can be divided into either gen-
eralized (absence), focal (complex partial), or other. The
‘epileptic twilight state’, during which there is intact arousal
with impairment of attention, can represent the clinical
overlap between generalized and focal NCSE [12]; the dis-
tinction often rests in the electrographic findings. Nonconvul-
sive SE should be considered in the differential diagnosis of
coma, as in a recent study at the Medical College of Virginia,
in which 8% of the patients in coma were in NCSE [15].
Prolonged focal seizures, such as isolated hand jerking, asso-
ciated with intact consciousness, comprises simple partial
SE. Some authors conceptualize this entity as a separate cat-
egory, while others include it as a subtype of NCSE [16].
Etiologies
The causes of SE are varied. Table 1 shows the etiologies of
SE in an urban hospital-based population [16]. Although the
data on causes of status, reported by DeLorenzo (Table 2),
show some correspondence, there are discrepancies such as
the higher proportion of cerebrovascular disease, anoxia, and
hypoxia [17]. These data sets include only the adult popula-
tion. In children, up to 51% are secondary to infectious etiolo-
gies [16].
Epidemiology, morbidity, and mortality
There have been two recent, prospective, population-based
epidemiologic studies of SE. The EPISTAR (a population-
based survey of SE in the French speaking part of Switzer-
land) study from Switzerland showed an incidence of about
10 cases per 100,000 people annually [18]. The population
in this study, however, was principally white, and cases of
anoxic encephalopathies were excluded. In the prospective
population-based study conducted at the Medical College of
Virginia, the incidence of SE was found to be 41 cases per
100,000 people [17] (Fig. 1). This would translate to over
100,000 cases of SE within the United States annually [19].
Reports on the mortality of SE range from a few percent to
over 50% [20]. The Richmond group found a mortality rate of
22% (corresponding to 22,000–42,000 deaths per year in
Table 1
Data on the etiology of status epilepticus in an urban hospital-
based practice
Etiology Percent of cases
AED non-compliance 26
Alcohol related 24
Drug toxicity 10
CNS infection 8
Cerebral tumor 6
Trauma 5
Refractory epilepsy 5
Stroke 4
Metabolic abnormalities 4
Cardiac arrest 4
Idiopathic 5
AED, anti-epileptic drugs; CNS, central nervous system. Data adapted
from Neurology [16].
Table 2
Data on the etiology of status epilepticus in a hospital and
community
Etiology Percent of Cases
Withdrawal of anticonvulsants 25
Cerebrovascular disease 23
Remote symptomatic 19
Alcohol withdrawal 15
Metabolic disorders 13
Hypoxia 12
Infectious disorders 8
Tumors 5
Anoxia 4
Trauma 3
Hemorrhage 2
Drug overdose 2
Idiopathic 4
Data adapted from Churchill Livingstone [17].the US) with the primary predictors of poor outcome being
anoxia, prolonged seizure (greater than one hour in duration),
and advanced age (Fig. 1) [21]. Mortality in the Swiss group
was lower (7.6%), which is most likely to be secondary to the
exclusion of anoxic encephalopathies [18].
Pathophysiology of SE
As a result of sympathetic overdrive, the body responds to
GCSE with both systemic and cerebral effects, whereas, to
NCSE, systemic effects are more limited. Systemic effects of
GCSE are summarized in Table 3. In the initial phase of
GCSE, blood pressure, glucose, and lactate increase, and
pH decreases. After this initial phase, at approximately 30
minutes, a second phase begins. During this second phase,
blood pressure and glucose normalize (sometimes decreas-
ing even further), lactate normalizes, and respiratory compro-
mise and hyperthermia ensue [22].
In both animal models and humans, GCSE has been shown
to result in damage to the brain [3,22,23]. The reasons for
this damage have not been completely elucidated; however,
several contributing factors are believed to exist. Some of the
systemic manifestations described in Table 3 can play a con-
tributory role. Meldrum et al. showed that hyperthermia
causes damage to the hippocampus and cortex [24]. Addi-
tionally, it has also been shown that reduction of temperature
results in shorter duration of SE and less damage [25]. Ini-
tially during SE, there is increased cerebral blood flow to
meet the elevated demands; however, as the cerebral blood
flow falls, there is a mismatch between blood supply and the
utilization of oxygen and glucose, resulting in a lower energy
state and metabolic–substrate mismatch [22]. It is important
to note that in experiments where systemic factors are con-
trolled, there is still damage to the brain [2,24].
An area of expanding research is excitotoxic-induced cell
injury, an important cause of damage to neurons [26]. The
damage to neurons is based on a complex interplay of multiple
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Figure 1
A graphical representation of mortality and incidence for four
population groups. These data are adapted from Neurology [19] and
Epilepsia [21].
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Table 3 
An overview of the systemic effects of status epilepticus
System Effects
Lungs Due to both metabolic and respiratory acidosis, the pH of arterial blood gases (ABG) is often found to be below 
normal in SE. Aminoff and Simon found that 59/80 (84%) of the patients with useable ABG information had pHs 
below 7.35 [43]. They suggest that the aberrations in pH may not be of clinical significance or of prognostic 
value.
In animal studies, pulmonary vascular pressure has been found to be elevated in SE [44] and may contribute to 
pulmonary edema [45]. 
Heart The sympathetic overdrive can cause tachycardia. In a study by Boggs, potentially fatal arrhythmias were reported in 
58% of the patients [46].
In a recent study, Boggs et al completed hemodynamic monitoring in SE patients 24 hours prior to their death, and 
found that there were two distinct groups with disparate cardiac manifestations [47].In the group with a lower 
proportion of previously discovered atherosclerotic disease (ASHD), there was acute cardiac decline without a 
significant drop in mean arterial pressure (MAP) or heart rate (HR). The second group, 90% of whom had a 
history of multiple risk factors for ASHD, showed a gradual decrease in MAP and HR prior to death.
Muscle As a result of continued seizure activity, conversion to anaerobic metabolism contributes to lactic acidosis [3].
Blood chemistries De-margination of neutrophils occurs with the stress of seizing. In patients without underlying infection, elevated white
blood cell counts (above the upper laboratory limit) were present in as many as 63% in one study [43].
Vital signs
Blood pressure The initial phase of SE results in an increased systemic blood pressure with an increase in peripheral vascular 
resistance [43]. As the status becomes prolonged, the blood pressure will normalize or even begin to fall with 
resultant hypotension.
Temperature As the seizure progresses, the body’s core temperature elevates. Aminoff and Simon looked at the temperature of 
90 patients in SE. Of these, only 8 had temperatures below 98°F, only 3 had fever secondary to known infection, 
and over 40 had temperatures above 100.5°F, (with two of the temperatures up to 107°F) [43].
Respiratory rate The patient in SE often has a transient change in respiratory rate and tidal volume [22].factors. Significant to this process is the inhibition of γ-
aminobutyric acid (a principle inhibitory neurotransmitter), and
the excessive action of glutamate (an excitatory neurotransmit-
ter). Additionally, apoptosis is likely to play a role in cell death
during SE. Given the probability of cerebral injury, it is impera-
tive for the clinician to recognize and treat SE expeditiously.
Treatment of acute status epilepticus
Basic life support
Airway, breathing, and circulation should be established
immediately. Intravenous access, while sometimes difficult to
achieve in an actively seizing patient, should be obtained.
Glucose should be given empirically along with thiamine in
alcoholic or otherwise malnourished patients. Laboratory
studies should include basic chemistry, blood glucose, anti-
convulsant levels, blood and urine toxicologic screen, com-
plete blood count, and urine analysis for evidence of infection.
The treatment of SE, however, should not be delayed while
these tests are pending.
Benzodiazepines
Benzodiazepines, usually either diazepam or lorazepam,
remain the first-line control for acute SE (ASE). No significant
difference has been found between the rate of seizure control
when lorazepam has been compared with either diazepam
alone [27] or diazepam plus phenytoin [8]. However,
lorazepam is believed to bind more tightly to receptors in the
brain and therefore has a longer duration of action and less
risk of recurrent seizures [28]. All benzodiazepines carry the
risk of respiratory depression and hypotension, and therefore
the clinician should be prepared to intubate or give pressors
if necessary. Diazepam is given at a dose of 10–20 mg;
lorazepam is given in 2 mg increments at approximately three-
minutes intervals. If seizures have not terminated after 8 mg of
lorazepam, another agent should be started.
Midazolam is a newer benzodiazepine that is associated with
a very favorable hemodynamic and pharmacokinetic profile
[29]. Its major advantage over lorazepam in the acute setting
is that its high water solubility and rapid onset of action when
given intramuscularly make this an attractive choice when
secure intravenous access is unobtainable [28]. Its use in
refractory SE will be discussed below.
Fosphenytoin
Traditionally, phenytoin alone at 20 mg/kg intravenous infu-
sion has been considered an appropriate first-line option in
the treatment of ASE. We recommend it be only used as a
second-line agent after a faster acting benzodiazepine has
been tried. Infusion rates are limited to 50 mg/min secondary
to the potential side effects of arrhythmia and hypotension.
Conversely, fosphenytoin (a water-soluble phosphate ester
prodrug of phenytoin with a neutral pH) can be delivered at
150 phenytoin-equivalent mg/min with essentially no risk of
reaction at the infusion site. Because it is water soluble, it
does not need a propylene glycol vehicle. It is 100% bioavail-
able when given either intravenously or intramuscularly, and it
is quickly converted by phosphatases to phenytoin once it is
in the vascular compartment [30].
In one small study of GCSE, fosphenytoin was associated
with a success rate of 93.8% in terminating seizures [31].
Studies have shown that therapeutic plasma concentrations
of phenytoin can be achieved more rapidly with fosphenytoin
that phenytoin when given at 15–20 mg/kg [31]. This is prob-
ably related to three factors: faster rate of infusion; displace-
ment of protein-bound phenytoin; and rapid conversion of
prodrug to phenytoin (half-life of 8.1 min) [32]. Although fos-
phenytoin is a more expensive alternative [33], the cost of
treating complications from the use of intravenous phenytoin
can be substantially higher [34].
Barbiturates
The Veterans Administration Cooperative study showed no
significant difference in efficacy between lorazepam
(0.1 mg/kg) and phenobarbital (15 mg/kg) [8]. However, it
also showed that if a patient did not respond to lorazepam or
phenytoin, the response rate to phenobarbital was only 2.1%
(unpublished data). We therefore recommend a more defini-
tive treatment strategy for patients that have not responded to
one, or at most two, first-line agents.
Treatment of refractory status epilepticus
Refractory SE is defined as ongoing seizures despite the use
of two first-line agents, usually a benzodiazepine plus either
phenytoin or phenobarbital. Definitive therapy often requires
doses of medications that cause respiratory suppression and
hypotension, so patients should be intubated and transferred
to an intensive care unit if this has not already been done.
Treiman et al. showed that respiratory suppression requiring
mechanical ventilation occurred in 18.9%, and pressor
support was needed in 32.6% of patients treated for SE [8].
Patients at this stage of SE require EEG monitoring, since the
physical exam is clouded by the use of paralytics for intuba-
tion and the potential for electromechanical dissociation.
The traditional goal of therapy has a burst suppression pattern
on EEG for 12–24 hours before attempting to taper medica-
tions. There are no convincing prospective data to suggest
that a burst suppression pattern is required to control or to
prevent recurrent seizures [35], thus we recommend seizure
suppression as a goal, regardless of the EEG background.
Pentobarbital
Pentobarbital, with a loading dose of 5–12 mg/kg followed by
an infusion of 1–10 mg/kg, is extremely effective in producing
coma and achieving burst suppression on EEG. Maintenance
therapy of a longer-acting anticonvulsant is continued during
this time in anticipation of reversing coma as soon as clini-
cally feasible. High doses of barbiturates can cause poor
chemotaxis of white cells, paralysis of respiratory cilia, and
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detecting infection and weaning the medication as soon as
safely possible. Although the half-life of pentobarbital is 90
hours, awakening begins within a few hours after the plasma
concentration begins to fall.
Midazolam
Numerous clinical studies have shown that midazolam bolus
(0.1–0.3 mg/kg) followed by continuous infusion
(0.05–2.0 mg/kg/hour) rapidly controls seizures that have not
responded to traditional first, second, and even third-line
agents [36,37]. Reports of clinically significant hypotension
are rare, and sedation is rapidly reversed after infusion is
stopped. Prolonged use of midazolam is limited by tachyphy-
laxis requiring increasing doses to maintain the desired EEG
tracing. Additionally, midazolam accumulates in critically ill
patients; with prolonged usage, the half-life of the terminal
phase can be three to eight times the reported half-life of two
to six hours [38]. In a small retrospective study, Prasad et al.
found that for patients with an APACHE II (Acute Physiology
and Chronic Health Evaluation II) score greater than or equal
to 20, treating refractory SE with midazolam may have a lower
mortality than that associated with propofol [39].
Propofol
Several studies and case reports document the efficacy of
propofol in the treatment of refractory SE, GCSE, NCSE, and
complex partial SE [40–42]. Propofol is fast-acting, highly
lipid soluble, and has little propensity to accumulate. An initial
dose of 3–5 mg/kg is followed by a maintenance dose of
1–15 mg/kg/hour, as required for seizure control. Abrupt dis-
continuation of infusion has been associated with recurrent
seizures. Hypotension, hypertriglyceridemia, and worsening
of anemia have also been reported with this agent. Two small
studies have shown an interesting, but insignificant, increase
in mortality among SE patients treated with propofol versus
midazolam or high dose barbiturates. Future studies are
needed to better elucidate this issue.
Conclusion
As the issue of SE is often faced by practitioners of critical
care, it is imperative that SE be recognized and treated as a
medical emergency. Given the complex pathophysiology,
being able to abort SE will contribute to a decrease in the
systemic effects and neurologic injury. First line treatment
with benzodiazepines, followed by the other agents dis-
cussed above, provide the maximal potential for successful
management of SE.
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